Evidence mapPaperPMID 31069057Full record

ReviewF1000Research2019

Recent advances in the understanding and management of polycystic ovary syndrome.

Ana L Rocha, Flávia R Oliveira, Rosana C Azevedo, Virginia A Silva, Thais M Peres, Ana L Candido, Karina B Gomes, Fernando M Reis

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in F1000Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04867252 (Effects of Combined Resveratrol and Myo-inositol on Altered Metabolic, Endocrine Parameters and Perceived Stress in Patients With Polycystic Ovarian Syndrome), which is not on this map. Cited by 46 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 4 pooled it
13.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04867252 phase2completednot on this mapstarted 2021, after this paper: background citation

Effects of Combined Resveratrol and Myo-inositol on Altered Metabolic, Endocrine Parameters and Perceived Stress in Patients With Polycystic Ovarian Syndrome

TypeinterventionalSponsorKhyber Medical University PeshawarRan2021 to 2021Enrolled88ConditionsPCOSArmsResveratrol (1000mg twice a day), Myoinositol 1000mg (Twice a day), Metformin (500 mg Twice a day), Pioglitazone (15 mg Twice a day)
3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 4 syntheses or guidelines pooled it, 141 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Ana L RochaDepartment of Obstetrics and Gynecology, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Flávia R OliveiraDepartment of Obstetrics and Gynecology, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Rosana C AzevedoDepartment of Internal Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Virginia A SilvaDepartment of Obstetrics and Gynecology, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Thais M PeresDepartment of Obstetrics and Gynecology, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Ana L CandidoDepartment of Internal Medicine, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.
Karina B GomesDepartment of Clinical and Toxicological Analysis, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.ORCID 0000-0002-6870-2063
Fernando M ReisDepartment of Obstetrics and Gynecology, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.ORCID 0000-0002-9258-7472
Universidade Federal de Minas Gerais · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polycystic ovary syndrome (PCOS) is a multifaceted condition characterized by chronic anovulation and excess ovarian activity, in contrast to other causes of anovulation that involve ovarian dormancy or primary insufficiency. Recent studies indicated that PCOS is associated with low-grade chronic inflammation and that women with PCOS are at increased risk of non-alcoholic fatty liver disease. The inflammatory and metabolic derangements associated with PCOS are explained in part by the coexistence of insulin resistance and obesity but are further fueled by the androgen excess. New insights into the regulation of hormones and cytokines in muscle and fat tissue support the concept that PCOS is a systemic syndrome. The therapeutic plan should be tailored to the patient phenotype, complaints, and reproductive desire. Of note, the aromatase inhibitor letrozole seems to be more effective than the reference drug clomiphene citrate to treat infertility due to PCOS. Integral management by a multidisciplinary team may help the patients to adhere to lifestyle interventions and thereby reduce body adiposity and recover their metabolic and reproductive health.

Indexed as

Insulin ResistanceAromatase InhibitorsClomipheneFemaleHumansLetrozoleObesityPolycystic Ovary SyndromeAromatase InhibitorsClomipheneLetrozoleinfertilityinsulin resistancemenstrual irregularityPCOSpolycystic ovary syndrome

Identifiers

PMID31069057
PMCPMC6489978
OpenAlexW2940491682

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.